ViroStatics Acquires Library of Anti-Cancer/Antiviral Compounds From the University of Siena
4/14/2009 11:58:46 AM
SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics srl, a clinical stage biotechnology company developing novel therapeutics for viral and other chronic diseases, announced today that it has obtained an exclusive license to a library of 300 compounds developed by Professor Maurizio Botta (University of Siena) in collaboration with Professors Silvia Schenone (University of Genova) and Giovanni Maga (IGM-CNR, Pavia) and to the patents associated therewith. The library consists of specifically designed molecules targeting key enzymes and processes involved in both cancer and viral diseases. ViroStatics will identify and develop candidate compounds with activity against HIV (the virus that causes AIDS), hepatitis C, and other viruses using the Company’s proprietary screening methodologies. Specific terms of the license agreement were not announced.
comments powered by